Needham Initiates Coverage On Clover Health Investments with Buy Rating, Announces Price Target of $6
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Needham analyst Matthew Shea initiates coverage on Clover Health Investments (NASDAQ:CLOV) with a Buy rating and announces Price Target of $6.
Needham analyst Matthew Shea initiates coverage on Clover Health Investments (NASDAQ:CLOV) with a Buy rating and announces Price Target of $6.
